The FDA has approved Takeda’s Orzeyful (oveporexton) for narcolepsy type 1 — the first medicine that targets the underlying cause of the disorder rather than just its symptoms.

Cleared on August 6, 2026, Orzeyful works by amplifying orexin-2, a brain protein regulating wakefulness and alertness.

What narcolepsy type 1 is

People with narcolepsy type 1 lose the neurons that make orexin, so a drug boosting orexin signalling addresses the root problem.

The loss is thought to be autoimmune. A relatively small population of neurons in the hypothalamus — tens of thousands of cells — is destroyed, and because those neurons do not regenerate the deficiency is permanent.

Orexin’s function is to stabilise the boundary between sleep and wakefulness. Without it, the brain does not simply become sleepy; it loses the ability to hold a state cleanly, so elements of sleep intrude into waking and vice versa.

That explains symptoms that otherwise look unrelated — sudden sleep onset, hallucinations at sleep boundaries, sleep paralysis, and fragmented night-time sleep despite overwhelming daytime sleepiness.

Why cataplexy defines the condition

The drug also reduced cataplexy — the sudden muscle weakness that distinguishes type 1 from type 2.

Cataplexy is muscle paralysis, normally confined to REM sleep, intruding into full wakefulness. It is triggered by strong emotion, frequently laughter, and can range from a slack jaw to complete collapse while the person remains conscious throughout.

It is the clearest demonstration of what orexin loss does: a sleep mechanism firing at the wrong time because nothing is holding the states apart.

Why this differs from existing treatment

In large trials Orzeyful was significantly better than placebo at keeping patients awake and reduced cataplexy, and was generally well tolerated.

Every prior treatment was symptomatic and worked through unrelated mechanisms. Stimulants promote wakefulness by acting on dopamine and norepinephrine, with the tolerance, cardiovascular effects and abuse potential that entails. Certain antidepressants suppress cataplexy by affecting REM sleep. Sodium oxybate consolidates night-time sleep.

None restores the missing signal. Replacing orexin activity treats the defect rather than compensating around it — the same conceptual shift as replacing a missing hormone rather than managing its consequences.

Not on shelves quite yet

Before launch, the DEA must complete a scheduling review, which can take up to 90 days.

Scheduling determines what controls apply — prescription limits, refill restrictions, record-keeping. It is routine for drugs acting on the central nervous system, and the outcome matters practically: a heavily scheduled drug is harder for patients to obtain consistently, which for a chronic condition affects real-world use.

A new, high-value class

Orzeyful opens what analysts see as a multibillion-dollar market. Jefferies projects peak annual sales around $2 billion, with estimated pricing of $142,000–$250,000+ per patient a year.

That pricing invites scrutiny for an oral small molecule — a category usually far cheaper than biologics or cell therapies. The justification offered for such prices is typically small population, high unmet need and transformative benefit, and narcolepsy type 1 meets those criteria more clearly than some.

Payer resistance is likely nonetheless, and access will depend on how restrictively coverage is written.

The competition

Rivals are close behind: Eisai has its own candidate, Eli Lilly bought Centessa Pharmaceuticals for $6.3 billion to enter the space, and Alkermes is testing alixorexton across narcolepsy and idiopathic hypersomnia.

The Alkermes programme is strategically notable because idiopathic hypersomnia is a larger population with normal orexin levels — so an orexin agonist there would work as an enhancer rather than a replacement, a broader and less certain proposition.

The diagnostic delay this could expose

An approval of this kind interacts with a long-standing problem in narcolepsy care: patients wait years for a diagnosis.

Delays of a decade or more between symptom onset and correct diagnosis have been widely documented. Excessive daytime sleepiness is common and usually attributed to poor sleep habits, depression or other conditions, so the specific diagnosis is rarely considered early.

Cataplexy is nearly definitive when recognised and is frequently missed. Patients do not always report it, having no reason to connect knee-buckling on laughter to sleepiness, and clinicians unfamiliar with the condition may not ask.

The relevant consequence is that a first-in-class drug entering the market creates commercial incentive to find undiagnosed patients — disease-awareness campaigns, physician education, screening tools. That improves diagnosis for a genuinely underdiagnosed condition, and it is promotion, so the accuracy of what gets communicated matters. A condition affecting a small population being marketed as widely underdiagnosed is a pattern that has produced both real benefit and real overdiagnosis in other therapeutic areas.

Being first gives Takeda a head start in a fast-emerging field. Regulatory news, not medical advice.